Showing 1431-1440 of 1477 results for "".
- User-Friendly Visual-Acuity Chart Shows Good Agreement With Existing Chartshttps://modernod.com/news/user-friendly-visual-acuity-chart-shows-good-agreement-with-existing-charts/2476405/The Runge near-vision card is user-friendly and shows good agreement with the Early Treatment Diabetic Retinopathy Study (ETDRS) and Snellen visual-acuity charts, researchers report, according to Reuters Health. “The Runge nea
- Allergan Responds to Public Shareholder Letterhttps://modernod.com/news/allergan-responds-to-public-shareholder-letter/2476274/Allergan issued the following statement from its Board of Directors in response to a public shareholder letter from Appaloosa hedge fund manager David Tepper earlier this week that stated the drugmaker should consider a merger or selling itself if it is “unable or unwilling to hold manageme
- Center for Vision and Population Health at Prevent Blindness Established to Implement Strategies to Address Eye Healthhttps://modernod.com/news/center-for-vision-and-population-health-at-prevent-blindness-established-to-implement-strategies-to-address-eye-health/2476154/Healthy vision can be a key component to independence and well-being for people of all ages. However barriers such as poor access to eye care, lack of insurance coverage, and inconsistent policies for eye health can prevent early detection and treatment of eye disorders. Prevent Blindness,
- Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Diseasehttps://modernod.com/news/novaliq-raises-new-capital-to-accelerate-the-commercialization-of-its-lead-products-for-dry-eye-disease/2479793/Novaliq announced it has raised $53 million to further support its late-stage products and earlier pipeline programs. Since inception, Novaliq has raised $115 million. The new investment is done by its lead investor dievini Hopp BioTech Holding, an active investor in Life and Health Scienc
- Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-campaign-to-spotlightsight-in-honor-of-world-sight-day/2479805/Sight is the most prized of all human senses. Yet, there are many people who do not fully experience the wonder of this gift. Nearly 285 million people around the world face impaired vision, and 80 percent of those cases are preventable with early diagnosis and treatment. That’s why Johnson
- Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trialhttps://modernod.com/news/aldeyra-therapeutics-announces-positive-results-from-phase-2b-dry-eye-disease-clinical-trial/2479841/Aldeyra Therapeutics announced positive results from its phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease. “The early onset and broad activity observed in the phase 2b clinical trial sugg
- Contact Lens Companies Seek Summary Judgment in Lawsuit Over Minimum Pricinghttps://modernod.com/news/contact-lens-companies-seek-summary-judgment-in-lawsuit-over-minimum-pricing/2479910/Three contact lens companies and a distributor, who are defendants in a class-action lawsuit over pricing, filed a motion seeking a summary judgment in the matter in U.S. District Court for the Middle District of Florida here earlier this week, according to a
- Some Companies Cancel, Reduce Planned Price Hikes Amid Continued Pressure Over US Drug Costs: Reporthttps://modernod.com/news/some-companies-cancel-reduce-planned-price-hikes-amid-continued-pressure-over-us-drug-costs-report/2480031/Novartis, Gilead Sciences, Roche, and Novo Nordisk have advised California health plans in recent weeks that the companies are rescinding or reducing previously announced price increases on at least 10 drugs, Bloomberg reported Tuesday. The moves come after California introduced legislation earli
- Novartis CEO Says Drugmaker’s Deal With Trump Lawyer Was a “Mistake”https://modernod.com/news/novartis-ceo-says-drugmakers-deal-with-trump-lawyer-was-a-mistake/2480155/In an internal email sent to employees, Novartis CEO Vasant Narasimhan apologized for the $1.2-million agreement the company made with President Donald Trump’s private lawyer Michael Cohen early last year in a bid to gain insight into US healthcare policy under the new administration. <
- Diopsys: Study Highlights the Important Role of PERG in Evaluation of Manifest and Suspected Glaucomahttps://modernod.com/news/diopsys-study-highlights-the-important-role-of-perg-in-evaluation-of-manifest-and-suspected-glaucoma/2480170/Pattern electroretinography (PERG) is again revealed as a powerful tool for evaluating patients with early stage glaucoma, particularly glaucoma suspects, according to a news release from Diopsys. According to the latest study published in Current Ophthalmology Reports by Porciatt
